当前位置:
X-MOL 学术
›
Nat. Rev. Rheumatol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Vasculitis syndromes: Tocilizumab — a new frontier for GCA therapy
Nature Reviews Rheumatology ( IF 29.4 ) Pub Date : , DOI: 10.1038/nrrheum.2017.150 Matthew J. Koster , Kenneth J. Warrington
Nature Reviews Rheumatology ( IF 29.4 ) Pub Date : , DOI: 10.1038/nrrheum.2017.150 Matthew J. Koster , Kenneth J. Warrington
Vasculitis syndromes: Tocilizumab — a new frontier for GCA therapy
中文翻译:
血管炎综合征:Tocilizumab — GCA治疗的新领域
血管炎综合征:Tocilizumab — GCA治疗的新领域
更新日期:2017-09-12
Nature Reviews Rheumatology, Published online: 7 September 2017; doi:10.1038/nrrheum.2017.150
An unmet need exists for effective glucocorticoid-sparing agents for the treatment of giant cell arteritis (GCA). Tocilizumab, the first intervention to demonstrate substantial therapeutic benefits for patients with newly diagnosed or relapsing GCA, is changing the landscape of treatment and ushering in a new era of biologic therapy.
中文翻译:
血管炎综合征:Tocilizumab — GCA治疗的新领域
血管炎综合征:Tocilizumab — GCA治疗的新领域
《自然评论风湿病》,在线发布:2017年9月7日;doi:10.1038 / nrrheum.2017.150
对于有效的糖皮质激素保留剂用于巨大细胞动脉炎(GCA)的治疗,存在未满足的需求。Tocilizumab是首次证明对新诊断或复发的GCA患者具有实质性治疗益处的干预措施,正在改变治疗方法,并开创了生物治疗的新时代。